New Report Shows Over 3,200 Clinical Trials of Medicines Conducted by Indiana Research Institutions Since 1999
Research Supported by Biopharmaceutical Companies Boosts Indiana Economy, Benefits Local Patients
WASHINGTON, D.C. (June 4, 2013) – Working in collaboration with Indiana clinicians and research institutions, America’s biopharmaceutical research companies have conducted 3,266 clinical trials of new medicines in Indiana over the last 13 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The report – “Research in Your Backyard: Pharmaceutical Clinical Trials in Indiana” – was released today at a news conference with Indiana Governor Mike Pence at Covance, a clinical research facility and biopharmaceutical services company in Greenfield.
Governor Pence, Chip Davis, PhRMA Executive Vice President for Advocacy, and Andrew Dahlem, Ph.D., Lilly Research Laboratories Vice President and Chief Operations Officer, shared their perspectives on the importance of biopharmaceutical research and life sciences in the state.
“Indiana’s life sciences industry has tremendous potential for growth,” said Governor Pence. “We are actively working to expand the partnership among life sciences and biopharmaceutical companies and our state’s universities and hospitals to grow the economy, to attract and retain talent, and to address the critical health issues we face today.”
A BioCrossroads report shows that the primary life sciences industries supported more than 64,000 pharmaceutical sector positions. Nearly 17,800 of the pharmaceutical jobs involved direct employment and about 46,500 were jobs supported by biopharmaceutical companies through statewide business arrangements. And the economic impact of the biopharmaceutical sector extends far beyond jobs. Pharmaceuticals accounted for nearly $5 billion of the $7.4 billion in Indiana life sciences exports in 2009. These exports nearly tripled from $2.5 billion to $7.4 billion from 2002 to 2009, ranking Indiana as third-highest among the states, behind California and Texas, according to BioCrossroads. Additionally, We Work for Health data released last fall revealed that more than $1.8 billion was invested in Indiana by the 17 surveyed biopharmaceutical companies in 2011.
“In addition to the economy, patients have been the beneficiaries of the research our companies have conducted in Indiana,” said Davis. “Working with local research institutions across the state, our companies have conducted over 1,750 clinical trials since 1999 just on the most debilitating chronic diseases – cancer, diabetes, heart disease, stroke, mental illnesses and asthma.”
Increasingly, medicines clinically tested in Indiana and across the country are cutting-edge biotechnology treatments.
“Our growing understanding of the molecular underpinnings of disease, coupled with new scientific approaches to developing medicines, gives us the capacity to create safer and more effective medications and improves our ability to predict and even prevent disease,” said Davis. “It’s impressive that a great deal of that research is underway here in Indiana.”
The report highlights how clinical trials are addressing the serious challenges of chronic disease:
- In 2011, more than 10 percent of the state’s adults had diabetes, according to the state Department of Health. Currently, 33 clinical trials of potential new treatments for diabetes are recruiting patients in the Hoosier State.
- In 2010, nearly 13,000 residents died from some form of heart disease and 3,077 died from a stroke, according to the Indiana Department of Health. Twenty heart disease and seven stroke clinical trials are seeking Indiana patients.
- Nearly 227,000 adults live with serious mental illness in the state and about 71,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness. Thirty mental illness clinical trials are recruiting patients.
The findings also show that research institutions in Indiana are conducting clinical trials of new medicines in collaboration with biopharmaceutical companies, including:
- Cancer Care Center Inc., New Albany
- Central Indiana Cancer Centers, Carmel, Fishers, Indianapolis
- Children’s Center for Cancer and Blood Diseases, Indianapolis
- Indiana University Hospital, Indianapolis
- Indiana University School of Medicine, Indianapolis
- Oncology Hematology Associates of Southwest Indiana, Evansville, Newburgh
- Lafayette Regional Vein and Laser Center, Lafayette
- Deaconess Hospital-The Heart Group, Evansville
- Premier Healthcare, Bloomington
For a listing of all clinical trials recruiting patients and their locations in Indiana, consult the appendix of the “Research in Your Backyard” report, which can be found at http://www.phrma.org/innovation/research-in-your-backyard. Indiana clinical trial information can also be found at www.clinicaltrials.gov, the trials data base of the National Institutes of Health.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested over $500 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.
Find PhRMA Online:
- Website – http://www.phrma.org
- Facebook – www.facebook.com/PhRMA
- Blog – www.phrma.org/catalyst
- Twitter – www.Twitter.com/PhRMA and www.Twitter.com/PhRMApress
- YouTube – www.youtube.com/PhRMApress
For information on how innovative medicines save lives, visit: http://www.innovation.org
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org